Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

Autor: Christos G Papadopoulos, Paraskevi V. Voulgari, Alexandros A. Drosos, Spyros N Nikas, A N Georgiadis, Yannis Alamanos, Aliki I. Venetsanopoulou
Rok vydání: 2006
Předmět:
Male
musculoskeletal diseases
medicine.medical_specialty
Concise Report
Immunology
Joints/physiopathology
Arthritis
Blood Sedimentation
Antibodies
Monoclonal
Humanized
Drug Administration Schedule
General Biochemistry
Genetics and Molecular Biology
Arthritis
Rheumatoid
C-Reactive Protein/analysis
Rheumatology
Internal medicine
medicine
Adalimumab
Health Status Indicators
Humans
Immunology and Allergy
skin and connective tissue diseases
Adverse effect
Aged
Antirheumatic Agents/*administration & dosage/adverse effects/therapeutic use
Tumor Necrosis Factor-alpha/antagonists & inhibitors
Platelet Count
Tumor Necrosis Factor-alpha
business.industry
Antibodies
Monoclonal
Middle Aged
medicine.disease
Connective tissue disease
Infliximab
Surgery
C-Reactive Protein
Treatment Outcome
Antirheumatic Agents
Rheumatoid arthritis
Monoclonal
Arthritis
Rheumatoid/*drug therapy/immunology/physiopathology
Antibodies
Monoclonal/*administration & dosage/adverse effects/therapeutic use
Female
Joints
business
medicine.drug
Zdroj: Annals of the Rheumatic Diseases. 65:257-260
ISSN: 0003-4967
DOI: 10.1136/ard.2005.039099
Popis: OBJECTIVE: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. METHODS: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor alpha inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria. RESULTS: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months' adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study-two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study-one because of lack of efficacy and two owing to side effects. CONCLUSION: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued. Ann Rheum Dis
Databáze: OpenAIRE
Externí odkaz: